
Primaa is a MedTech company founded in 2018 that offers an AI-based platform for automated and accurate cancer diagnosis. Their technology leverages image analysis and deep learning to enhance detection of major cancer biomarkers, guiding personalized treatment. Key products include Cleo Breast and Cleo Skin, AI assistants designed to detect breast and skin cancer respectively. The platform improves pathologists' workflow by accelerating case reviews, prioritizing cases intelligently, and increasing diagnostic precision, ultimately advancing personalized medicine and patient outcomes. Primaa has achieved CE certification, published scientific articles validating their solutions, and collaborates with leading medical organizations. Their business model is primarily SaaS, targeting pathologists and healthcare providers.

Primaa is a MedTech company founded in 2018 that offers an AI-based platform for automated and accurate cancer diagnosis. Their technology leverages image analysis and deep learning to enhance detection of major cancer biomarkers, guiding personalized treatment. Key products include Cleo Breast and Cleo Skin, AI assistants designed to detect breast and skin cancer respectively. The platform improves pathologists' workflow by accelerating case reviews, prioritizing cases intelligently, and increasing diagnostic precision, ultimately advancing personalized medicine and patient outcomes. Primaa has achieved CE certification, published scientific articles validating their solutions, and collaborates with leading medical organizations. Their business model is primarily SaaS, targeting pathologists and healthcare providers.
Founded: 2018 (Paris, France)
Product focus: AI-powered digital pathology (Cleo Breast, Cleo Skin)
Regulatory milestone: Cleo Breast CE/IVDR certified
Business model: Primarily SaaS targeting pathologists and healthcare providers
Reported funding: $7.58M total (including $5.38M Series A, Nov 2024)
| Company |
|---|
Digital pathology and cancer biomarker detection
2018
Biotechnology Research
$5.38M
Reported November 2024 Series A to support development and international commercialization
Company reports a first equity round in 2019 with 50 Partners
“Has attracted institutional and angel investors across multiple rounds (includes 50 Partners and several other named investors in reporting)”
Qui sommes-nous ?
Primaa est une start-up medtech innovante développant des logiciels d’aide à la décision pour le diagnostic du cancer. Nos outils accompagnent les médecins anatomo-pathologistes pour réduire le temps de diagnostic et améliorer les chances de survie des patients. Pionnière dans son domaine, Primaa bénéficie d’un fort soutien de l’écosystème médical.
Le rôle
Nous recherchons un(e) Chef de projet déploiement EU & US pour piloter le déploiement et l’adoption de nos solutions auprès de nos clients (hôpitaux, laboratoires, centres diagnostiques) en Europe et aux États-Unis. Ce rôle clé garantit la réussite opérationnelle, l’adoption clinique et technique, et le respect des normes réglementaires (CE-IVDR, FDA, GDPR/HIPAA).
Responsabilités principales
Qualifications